Literature DB >> 7873821

The development of non-melanocytic skin cancers in people with a history of skin cancer.

D Czarnecki1, A Mar, M Staples, G Giles, C Meehan.   

Abstract

OBJECTIVE: To determine the incidence of new skin cancer formation in people who have had skin cancer removed. STUDY
DESIGN: A prospective study of Melbourne out-patients with histologically confirmed non-melanoma skin cancer (NMSC). All patients with NMSC seen by one author (D.C.) between November 1988 and November 1989 were entered into the study and reviewed regularly. New skin cancers were removed and recorded.
RESULTS: Four hundred and eighty-one patients were entered and 420 followed for at least 3 years. New NMSC developed in 60% (adjusted for losses) by the end of 3 years. A multivariate analysis determined that the main risk factor for new NMSC formation was the number of previous skin cancers that a patient had. Those who had had multiple skin cancers (3 or more) were at significantly greater risk than those with less than 3. Age, sex and type of NMSC were not risk factors for new skin cancer formation.
CONCLUSION: Patients with NMSC require long-term follow-up because of the risk of new skin cancer formation. Those with multiple NMSC need more careful follow-up, and possibly more frequent examinations, because they are at greater risk.

Entities:  

Mesh:

Year:  1994        PMID: 7873821     DOI: 10.1159/000246880

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  6 in total

1.  Randomized controlled trial of acitretin versus placebo in patients at high-risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251).

Authors:  Kunal C Kadakia; Debra L Barton; Charles L Loprinzi; Jeff A Sloan; Clark C Otley; Brent B Diekmann; Paul J Novotny; Steven R Alberts; Paul J Limburg; Mark R Pittelkow
Journal:  Cancer       Date:  2011-08-31       Impact factor: 6.860

2.  Validation Study of the AJCC Cancer Staging Manual, Eighth Edition, Staging System for Eyelid and Periocular Squamous Cell Carcinoma.

Authors:  Shiqiong Xu; Oded Sagiv; Maria Laura Rubin; Ho-Seok Sa; Michael T Tetzlaff; Priyadharsini Nagarajan; Jing Ning; Bita Esmaeli
Journal:  JAMA Ophthalmol       Date:  2019-05-01       Impact factor: 7.389

3.  Squamous cell carcinoma of the eyelids.

Authors:  M J Donaldson; T J Sullivan; K J Whitehead; R M Williamson
Journal:  Br J Ophthalmol       Date:  2002-10       Impact factor: 4.638

4.  Comparison of risk factors of single Basal cell carcinoma with multiple Basal cell carcinomas.

Authors:  Zahra Hallaji; Hoda Rahimi; Mostafa Mirshams-Shahshahani
Journal:  Indian J Dermatol       Date:  2011-07       Impact factor: 1.494

5.  Risk Factors and Clinicopathological Features for Developing a Subsequent Primary Cutaneous Squamous and Basal Cell Carcinomas.

Authors:  Magdalena Ciążyńska; Marta Pabianek; Martyna Sławińska; Adam Reich; Bogumił Lewandowski; Katarzyna Szczepaniak; Małgorzata Ułańska; Dariusz Nejc; Robert Brodowski; Michał Sobjanek; Witold Owczarek; Grażyna Kamińska-Winciorek; Dariusz Lange; Monika Słowińska; Katarzyna Wróbel; Andrzej Bieniek; Anna Woźniacka; Anika Pękala; Łukasz Kuncman; Magdalena Salińska; Marcin Noweta; Małgorzata Skibińska; Joanna Narbutt; Karol Ciążyński; Marta Lewandowska; Elżbieta Dziankowska-Zaborszczyk; Aleksandra Lesiak
Journal:  Cancers (Basel)       Date:  2022-06-23       Impact factor: 6.575

6.  Epidemiological characteristics and clinical course of eyelid squamous cell carcinoma patients from a large tertiary centre between 2009 and 2020.

Authors:  Annemarie Klingenstein; Christina Samel; Elisabeth M Messmer; Aylin Garip-Kuebler; Siegfried G Priglinger; Christoph R Hintschich
Journal:  Br J Ophthalmol       Date:  2021-03-12       Impact factor: 5.908

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.